Fully Human Antibody / TCR Platforms

Fully Human TCRs

T-cell receptors (TCRs) recognize antigenic peptides presented by MHC molecules and mediate antigen-specific T-cell responses. By recognizing peptides derived from intracellular proteins, TCRs expand the range of targets accessible to therapeutic intervention. TCR-based approaches include TCR-T cell therapies, soluble TCR therapeutics, and other TCR protein-based modalities.
  • 10+
    TCR Assets
  • 450+
    Antibody Asset Partnerships
Request Data Package Schedule a Meeting
related resource

on this page

  • Advantages of the RenTCR™ Platform for Fully Human TCR Discovery
  • RenTCR™ Platform Workflow for Fully Human TCR Discovery
  • Off-the-Shelf TCR Library Powered by the RenTCR™ Platform

Webinars

View All

    Posters

    View All

      Advantages of the RenTCR™ Platform for Fully Human TCR Discovery

      • Streamlined Screening Workflow:  The platform enables rapid identification and acquisition of natural TCRs with high specificity and reactivity.
      • Superior In Vivo & In Vitro Activity: The platform enables the identification and selection of TCRs with potent antitumor activity in both in vitro and in vivo studies, outperforming human donor-derived TCRs.
      • Broad, Ready-to-Use TCR Libraries: The platform facilitates the creation of off-the-shelf TCR libraries with broad HLA haplotype coverage to streamline subsequent development.
      • Significant Cost Advantage: The platform reduces costs compared with human donor-based TCR discovery methods.
      • Extended Platform Utility: The platform is also applicable for novel target and epitope discovery.
      Advantages of the RenTCR™ Platform for Fully Human TCR Discovery img

      RenTCR™ Platform Workflow for Fully Human TCR Discovery

      RenTCR™ Platform Workflow for Fully Human TCR Discovery img

      RenTCR™ platform-derived TCRs exhibit higher peptide sensitivity than human donor-derived TCRs

      RenTCR™ platform-derived TCRs exhibit higher peptide sensitivity than human donor-derived TCRs img
      IFN-γ production by TCR-transduced human T cells in response to stimulation with MAGEA1 peptide-loaded T2 cells. Human donor-derived TCRs include those in clinical development or reported in the literature. Data are normalized to maximum IFN-γ release and fitted to a four-parameter logistic model.

      HLA-A2.1/MAGE-A4-specific fully human TCRs exhibited greater antitumor activity than clinical-stage affinity-enhanced TCRs

      HLA-A2.1/MAGE-A4-specific fully human TCRs exhibited greater antitumor activity than clinical-stage affinity-enhanced TCRs img
      NDG immunodeficient mice were implanted with human HLA-A*02:01+ tumor cell lines A375 and SHP-77, both of which endogenously express MAGE-A4. Once the tumor volume reached 100 mm3, T cells expressing MAGE-A4-specific TCRs or mock T cells were administered (n = 6 mice/group), with T cells transduced with clinical-stage affinity-enhanced TCRs serving as positive controls. S.C.: subcutaneous injection; I.V.: intravenous injection; TIW: three times a week.

      Off-the-Shelf TCR Library Powered by the RenTCR™ Platform

      Target Type of Antigen HLA Immunization TCR Discovery & Sequencing In Vitro Functional Verification Epitope Identification Specificity Verification In Vivo Functional Evaluation
      MAGEA4/8 CTA HLA-A2.1
      MAGEA4 CTA HLA-A24.2
      PRAME CTA HLA-A2.1
      PRAME CTA HLA-A24.2
      NY-ESO-1 CTA HLA-A2.1
      MAGEA1 CTA HLA-A2.1
      MAGEA10 CTA HLA-A2.1
      KRAS G12V TSA HLA-A11.1
      KRAS G12D TSA HLA-A11.1
      HPV16 E6 Virus HLA-A24.2
      HPV16 E7 Virus HLA-A2.1
      MAGEC2 CTA HLA-A24.2
      COL6A3 TAA HLA-A2.1